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Abstract: Malaria drug trials conducted in endemic areas face a major 
challenge in their analysis: parasitaemia in blood samples collected 
after treatment may indicate a drug failure or originate from a new 
infection (NI) acquired after treatment. It is therefore vital to 
reliably distinguish drug failures from NI to obtain accurate estimates 
of drug failure rates. This is achieved in Plasmodium falciparum by 
comparing parasite genotypes obtained at time of treatment (the baseline) 
and on the day of recurring parasitaemia. Such 'PCR-correction' is 
required, even for new effective drugs, to obtain accurate failure rates. 
Despite its routine use in surveillance of drug resistance and in 
clinical drug trials, limitations inherent to the molecular genotyping 
methods has led some commentators to question the validity of current 
PCR-correction strategies. We describe and discuss recent developments in 
these genotyping strategies with particular focus on method validation 
and limitations.  Our aim is to update scientists from public and private 
bodies working towards the development, deployment and surveillance of 
new malaria drugs. We aim to promote discussion around these issues and 
argue for the adoption of improved standardized PCR-correction 
methodologies. 
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Dear Editor 
 
Thank you for sending us the reviewers’ comments. We address them in the following 
pages. We enumerate their comments for ease of cross reference, include their comments 
in italics and blue font, and provide our responses in plain text and black font. 
We would like to thank the reviewers for their valuable und constructive comments.  
 
Kind regards  
Ingrid Felger  
(on behalf of all co-authors) 
 
 
 
  
*Reply to Reviewers Comments
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Reviewer #1: The authors present the state of the art in malaria genotyping as it relates to 
clinical trials for antimalarials. The message is an important one that has been overlooked by 
clinical trialists, regulatory authorities and policy makers: current methods are limited and 
may mis-attribute genotypes and inaccurately reflect drug treatments.  
1.1 There are references here to unpublished results used as evidence and articles "in this 
issue" which I was not able to discern (pages 6 para 2, references to Jones et al to which this 
reviewer does not have a reference or access).  
We have deleted this cross reference on page 8. It referred to a manuscript that was 
submitted as a joint submission to Lancet Infectious Diseases together with this personal 
views article. It was deemed unsuitable for LID and is now under review in Antimicrobial 
Agents and Chemotherapy: 
Jones, S., K. Kay, E.M. Hodel, S. Chy, A. Mbituymuremyi, A. Uwimana, D. Menard, I. Felger, I. 
Hastings. Improving methods for analysing anti-malarial drug efficacy trials: molecular 
correction based on length-polymorphic markers msp-1, msp-2 and glurp. Submitted. 
The Jones et al. manuscript uses methodology previously published in: 
Jaki T, Parry A, Winter K, Hastings I. Analysing malaria drug trials on a per-individual or per-
clone basis: a comparison of methods. Stat Med 2013; 32(17): 3020-38. 
 
We therefore cite Jaki et al. 2013 (e.g. in caption to Figure 1) to allow readers access to the 
underlying methodology.   On page 8 of our article we have inserted  (“Jones and Hastings, 
personal communication”), which will be exchanged against the correct reference, should 
the AAC article be published before this one.  
Page 8: The paragraph on modelling has been revised as follows:  
 “Modelling provides a new approach to validate potential algorithms for 
interpreting PCR-corrected data. Pharmacological models can simulate a population 
of patients in a drug efficacy trial, their therapeutic outcomes, and the genotyping 
results that would occur at Day 0 and Day X.16 PCR-corrected failure rates were 
compared using several molecular correction approaches based on simulation 
models from Jaki and coworkers.16 The “2/3 approach” (i.e. only using glurp if msp1 
and msp2 gave concordant results) provided the best fit with the simulated 
treatment failure rates in a comparison to other molecular correction strategies 
(Figure 1). Adopting the 2/3 approach instead of the current WHO sequential typing 
method led to higher failure rate estimates but these were closer to the theoretical 
true failure rate. 
The current WHO/MMV method, and the new algorithms currently under 
investigation (Jones and Hastings, personal communication), all seek to define 
recurrent infections as either NI or a drug failure. 
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1.2 False impressions of drug failure in a clinical trial context is a major issue. Newer 
methods including NGS are touched upon as possibly being the solution. The major concern I 
have is that the authors would do well to convene a technical consultation with experts in 
the field including clinicians, method developers, NGOs in trials like MMV, policy makers etc. 
and then publish the results of the round table rather than this somewhat superficial piece. 
The "2/3 approach" is mentioned as a solution but there is insufficient evidence that it 
should be adopted without a fuller application to larger datasets beyond what is presented 
in Figure 1. 
 
We agree entirely with the comments listed by the Reviewer as “major concerns”. We 
reassure the Reviewer as follows: 
We wrote the article for LID primarily because we believe it will be of significant interest to 
the readership of LID, as it deals with two crucial facets of malaria control, namely drug 
efficacy trials and monitoring for emergent drug resistance. However, as recognised by the 
Reviewer, it also has a significant political aspect. We agree with the Reviewer that a 
“technical consultation” and “round table” discussion of key stakeholders will be necessary 
to reach a consensus on most appropriate methodology and we plan to organise and 
convene such a meeting. The problem is that such meetings require financial support and 
clear demonstration to donors and potential participants that there is a clear need for such 
a meeting; this article is designed to start this process. We are ideally placed to drive this 
process. Current recommendations originate from round table technical discussions held in 
Geneva in May 2007, supported by WHO and Medicines for Malaria Venture (MMV) and 
subsequently published as a WHO report i.e.  
World Health Organization (2008). Methods and techniques for clinical trials on antimalarial 
drug efficacy: genotyping to identify parasite populations. 
 
H-P Beck chaired that meeting, I. Felger was rapporteur, J. Möhrle was part of the 
secretariat and G. Snounou was a participant. More recently I. Hastings was asked by WHO 
via their TEG on Drug Resistance and Containment, to asses and evaluate the literature and 
methodology of correction in trials. We anticipate that this submission to LID would be the 
first stage of the process leading to a similar meeting being convened in the near future. We 
recognise that support for policy change, driven by scientific analysis, is one of the prime 
objectives of LID, hence our decision to submit in your journal. 
 
In addition, I. Felger and I. Hastings participated in the Technical Expert Group on Drug 
Efficacy and Response held at the World Health Organization, Geneva, Switzerland in June 
2017. The group discussed the issue of molecular correction and their key recommendation 
was: ““The Technical Expert Group (TEG) recommends that once the new analysis has been 
completed, the guidance on P. falciparum genotyping should be reviewed and revised if 
necessary” (Minutes available at https://www.who.int/malaria/mpac/mpac-oct2017-teg-drug-
efficacy-response-session3.pdf?ua=1.) 
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Page 10: As recommended by Reviewer 1 we suggest at the end of our paper that it is timely 
to convene another technical meeting to update recommendations for PCR-correction 
published in 2008 by WHO.  
“We suggest that improved understanding and technical developments since 
publication of the WHO/MMV consensus protocols (2008) makes it important that 
its recommendations should be updated. Another technical meeting should be 
convened, particularly to address the methodological requirements for drug 
registration trials that are more demanding than drug resistance monitoring studies. 
Regulatory trials require precise methodologies and should be implemented as state-
of-the-art. The present paper will serve as a basis for discussion towards a revised 
consensus.”   
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Reviewer #2: General comments: The aim of the review was to discuss the validity and 
limitations of genotyping strategies used to correct for cure rates in drug trials and efficacy 
of antimalarial drugs. This is to update stakeholders and to encourage discussions around 
the current challenges and advance an argument for improvement of strategies.  
 
This very well written review sets the status-quo on PCR correction during drug trials 
especially in highly endemic areas and during surveillance of drug efficacy in malaria 
endemic areas. The authors establish the fact that the US-FDA is lagging behind even with 
the current PCR-corrected cure rate although there is a general consensus on the relevance 
of the correction.  They discuss the biological principle behind PCR correction and the 
molecular markers used. The two major drawbacks to the currently used genotyping 
techniques were highlighted to be either biological or technical. Finally some very practical 
solutions on the way forward were offered. 
 
2.1 Page 9: An alternative method genotypes a large number of SNPs distributed over the 
entire genome (molecular barcode).33 All SNPs are genotyped by individual qPCRs using 
allele-specific probes and high-resolution melting curve analysis to distinguish nucleotides. 
Multi-clonal infections will yield mostly mixed signals and haplotypes for concurrent clones 
cannot be established for samples of high multiplicity. It should be mentioned that the 
molecular barcode is most suitable for clonal infections in low transmission areas.  
 
Page 9: We have expanded our previous statement and included the point raised by 
Reviewer 2: 
“Multi-clonal infections will yield mostly mixed signals and haplotypes for concurrent 
clones cannot be established for samples of high multiplicity. Barcodes could be 
suitable for clonal infections in low transmission areas but their use in higher 
transmission areas still needs to be validated.”   
We fully agree with Reviewer 2 in that no haplotypes can be reconstructed for multi-clone 
infections.  
 
2.2 Recommendations 
For the low clone detectability (due to sequestration observed within 48 hours) can we 
recommend samples for days 0, 1, 2 in addition to X and X+1 even from LM-negative 
individuals? 
We have addressed this issue in the original version of our manuscript on page 5, end of first 
paragraph. Owing to LID’s limitation in word count, we could not elaborate further on this 
topic. We would be very happy to include the paragraph presented below, in case we 
receive permission from editors to go beyond the word limits. 
Here is our response to Reviewer 2:  
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The practicalities of  genotyping two blood samples taken 24 h apart was discussed 
in length at the expert meeting in 2008. From an operational aspect this is 
considered impracticable and not feasible by sponsors as it would require detaining 
patients for 24 hours post-treatment, or asking them to return next day when they 
may still be symptomatic.  Moreover, there is invariably an ethical obligation to 
provide immediate treatment with rapidly acting ACTs, where parasites disappear 
after 8 hours post ACT treatment;  the likelihood of detecting minor clones at day 1 
and beyond then becomes very small. Therefore, the probability of catching what 
was sequestered on admission will be diminished, and this will be even more 
problematic for Day 2 samples.  In the perspective of Single Exposure Cures that are 
in the pipeline, obtaining PCR samples beyond Day 0 will become even more difficult. 
 
2.3 It is most unlikely to detect all low clones as a result of immunological processes such as 
sequestration; WI think we need some studies to estimate the variations in the estimates of 
cure rate and drug efficacy using the various PCR correction methods applied in the field. 
These could improve the recommended Bayesian models and incorporate the more realistic 
uncertainty around each approach. Also reporting of these uncertainties should be made 
mandatory.  
 
The biological constraints and limitations had been discussed in detail in our manuscript. 
This can be found on Page 4, section “Biological constraints resulting in undetected clones”. 
Page 9: We have extended the original version as follows:  
“Yet, biological constraints will remain the same, such as sequestration or detection 
limits for minority clones.” 
We agree in that it would be very useful to compare PCR-correction outcomes after various 
alternative genotyping methods have been performed in parallel on the same sample set.  
Even when different algorithms for analysing genotyping data are used, we argue that the 
results from all PCR-correction algorithms be presented. This discussion will be in a separate 
manuscript that originally had been suggested as a companion paper: Jones et al. submitted 
to AAC (see 1.1. above). 
We agree entirely with the basic point being made by the Reviewer (i.e. the need to 
compare and provide various methods of analysis) and we promoted this approach so that 
researchers have access to all different analyses and can find the one(s) most appropriate to 
their beliefs or which are most consistent with previous analyses.  
Given this request by Reviewer 2 for more comparative studies, we find it bewildering that 
in section 2.7 s/he later states that molecular correction data should not be collected, a 
strategy that would rob future researchers of access to these different analyses. 
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2.4 The general problem of PCR amplification bias before sequencing needs to be addressed. 
Gene or genomic region capture by Molecular Inversion Probes before amplification reduces 
the bias in the gene or region of interest and should also be considered in the NGS 
approaches. 
 
Page 9: We thank Reviewer 2 for a valuable contribution, which we have included by adding 
a reference to relevant literature (a recent P. falciparum publication on the use of Molecular 
Inversion Probes in genotyping: Aydemir et al. 2018)  
“Molecular inversion probes may be useful for highly multiplexed targeted 
sequencing.33 ” 
 
2.5 The authors should discuss the feasibility of NGS in most disease endemic countries. If 
PCR-correction is made so high-tech that only a handful of labs in the North can do it, it will 
not adequately serve the purpose of widely informing policy in disease endemic countries. 
 
We understand the point made by Reviewer 2 about limited access to NGS of laboratories in 
malaria endemic countries. Our paragraph on POSSIBLE USE OF ALTERNATIVE GENOTYPING 
TECHNIQUES on page 9 starts with: “This section briefly describes developments with great 
potential to improve genotyping of P. falciparum multiple-clone infections.” In this section 
we do not argue that NGS is recommended for PCR correction. We argue that the value of 
alternative techniques for PCR-correction deserves to be investigated. In our view it would 
be a great advance for regulatory trials in endemic regions if state-of-the-art techniques are 
employed that finally may overcome the limitations repeatedly raised over many years and 
described in our Personal View manuscript in detail.  
Page 9: We have modified the concluding paragraph in this section on alternative 
techniques (two sentences added are underlined):  
“Both these methods have the potential to improve detection of minority clones and 
overcome allelic suppression. Thus, these should be validated in clinical trials at high 
priority. In particular regulatory trials would benefit from state-of-the-art techniques 
that overcome the technical limitations stated above. Yet, biological constraints will 
remain the same, such as sequestration or detection limits for minority clones. For 
surveillance trials, optimized protocols of established typing techniques may be 
easier implemented than NGS-based methods in laboratories in endemic countries.” 
 
2.6 The authors discuss in details the technical limitations but fail to address the impact of 
the PCR-correction on the relevant downstream decisions. Indeed, the overall utility of PCR-
correction is based on the assumption that new infections will cause no harm to the patient 
or have no impact on the disease epidemiology. This assumption is probably not adequate.  
Reviewer 2 appears to have misunderstood our background section on PCR-correction. Just 
to be clear: we do not assume that “new infections will cause no harm to the patient”. All 
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trials to our knowledge are ethically obliged to treat patients returning with recurrent 
malaria during follow-up because most researchers, ourselves included, believe that any 
episode subsequent to treatment, whether a new infection or a recrudescence, can cause 
harm. The requirement to treat a patient presenting with malaria infection x days after 
treatment, does not depend on the molecular analysis. Treatment should be given either 
according to the study protocol (in a drug trial) or treatment guideline (in efficacy 
monitoring). 
PCR-correction has never been suggested to be used to inform treatment decisions at the 
point-of-care. Genotyping of recurrent parasitemia is generally performed on archived 
samples, weeks or months after the malaria episode. The purpose of genotyping is to better 
estimate drug efficacy in regions where episodes of infections during the follow-up period 
occur frequently.  
 
Page 3: To rule out any such misconception among readers, we have made this point 
explicitly clear by inserting the following sentence: 
“Genotyping is performed on archived blood samples at a later point in time and 
does not inform or influence treatment of recurrent parasitemia. Treatment is 
always given, either per protocol in clinical trials or according to local treatment 
guidelines in drug efficacy monitoring, for all parasitemic episodes.“  
 
2.7 Indeed, what difference does it make for a Physician working in a remote health post in 
Africa to know whether the parasites his patient is carrying are new or old? A number of 
studies show that the so-called "new infections" that are discarded from the PCR-corrected 
cure rates: 
1/ are likely to yield symptoms a few days after the end of the follow-up,  
2/ are associated with anemia 
3/may be involved in malaria transmission in the community 
Therefore, in this era of malaria elimination and ultimate eradication, and because it is 
technically challenging and of debatable public health benefit I am of the opinion that PCR-
correction is to be removed from trials for new antimalarial drugs. We should get back to 
plain microscopy or use species-specific PCR to check whether parasites are present or not 
after drug treatment (recrudescent or new infection altogether).  
 
We concur with the three points above raised by the reviewer and re-iterate that PCR 
corrections are not used to inform treatment. They do, however, provide public health 
officials with a rationale for the anti-malarial treatment regimens they adopt, and of equal 
importance, an early warning of failure of these regimens. We thus, feel that removing PCR 
correction from trials of new antimalarial drugs would be scientifically and ethically 
inappropriate. This view is held by most scientists and stakeholders involved in drug 
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development and clinical trials, and they fully accept the usefulness of PCR-correction to 
obtain more precise estimates of drug efficacy.  
The Reviewers comments are easily addressed, in particular with reference to comment 2.3 
above, where s/he requests (correctly in our opinion) that various analytic methods should 
be attempted and reported. We simply state that separating new infections from 
recrudescences provides readers with maximal information from a trial. If readers believe, 
as does this reviewer, that this distinction is unimportant they can simply sum the 
recrudescences and new infections to get the overall “failure rate”. If, like most people, they 
believe the two outcomes represent separate processes they have access to the corrected 
data. In other words, why deny readers access to such important information? 
In the following we provide a section on the rationale for PCR-correction. This is meant as a 
response to point 2.7. raised by Reviewer 2, but could also be included, rephrased, as a new 
section into our manuscript. This will take us over the word limit, so we leave it as an 
editorial decision.  
 
The need for molecular correction 
Molecular correction will not be used to guide the physician’s decision on treatment of a 
patient presenting with recurrent malaria. Genotyping is performed because it permits to 
estimate the therapeutic effectiveness of a drug in clearing existing infections, separately 
from its prophylactic effectiveness in preventing new infections. Malaria control and 
eliminating programmes require estimates of prophylaxis to predict their impact. The most 
likely end-users of clinical trials are national programme managers who, assuming they 
follow WHO guidelines, are mandated to change their first line antimalarial once failure 
rates exceed 10%. Because uncorrected failure rates include new infections, these managers 
could find themselves in a position where all available drugs are ‘failing’ on this metric and 
no rational basis for drug deployment would be left. We also argue that having recruited 
participants into a clinical trial, we have an ethical obligation to maximise the value of their 
participation, particularly since no further action on their part is required for molecular 
correction to occur (correction uses blood samples already provided by participants at the 
time of recurrence and treatment). While we recognise that different views will be held on 
how best to utilise molecular correction, our strongly-held personal view is that to wilfully 
ignore molecular correction is at best a missed opportunity to understand malaria 
treatment, prophylaxis and resistance and, at worst, at liability for effective public provision. 
 
To illustrate the need, we provide useful comparison (Table taken from Jones et al; see 
section 1.1. above) showing the difference between corrected and non-corrected estimates.  
Drug tested Uncorrected vs corrected failure rates Country/yr Ref 
AR-LF 54% vs 10% Burkina Faso, 2014 (34) 
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AS-AQ 42% vs 10% 
AS-AQ 17% vs 6% Congo, 2013 (35) 
AR-LF 22% vs 0% Tanzania, 2014 (36) 
AR-LF 13% vs 0% Benin, 2016 (37) 
AR-LF 9% vs 2% Mozambique, 2015 (38) 
AR-LF 2% vs 1% India 2015 (39) 
AR-LF 
AS-AQ 
16% vs 1% 
22% vs 5% 
Congo 2012 (40) 
 AR-LF, artemether plus lumefantrine; AS-AQ, artesunate plus amodiaquine 
Table: The need for molecular correction: a comparison of estimated drug failure rates obtained 
without correction vs with molecular correction performed according to the current WHO/MMV 
recommended algorithm. Failure rate was calculated as 1 minus the 28-day adequate clinical and 
parasitological response reported in the studies (data collated and provided by Drs Jörg Möhrle and 
Stephan Duparc). 
 
2.8 The new antimalarial drugs target product profiles should be oriented towards drugs 
that kill the existing parasites and prevent new infections for a reasonable length of time. 
We agree entirely but note that target product profiles of new drugs are not the topic of our 
manuscript. This has been extensively discussed in the following paper (DOI 10.1186/s12936-016-
1675-x) 
Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial target candidate and 
product profiles. Malaria J 2017; 16(1): 26. 
For example, their Figure 2.  
As this point is not directly relevant to our manuscript and owing to constraints in word counts, we 
did not include this additional aspect of drug development and the mentioned citation. 
 
2.9 I would request the authors to address the above points in the paper. 
 
We have done so, details above. 
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Reviewer #3: The authors present updates on PCR correction of clinical and parasitological 
outcomes in studies evaluating antimalarial drug efficacy, outline major limitations of the 
currently recommended method, and propose alternative methods to correctly distinguish 
between recrudescence and reinfection.  
 
Major comments: 
 
3.1 The authors advance very good technical arguments to demonstrate the limitations of 
the WHO-recommended method to distinguish between recrudescence and reinfection. 
However, the authors' recommendations seem to be applicable only (or mostly) in non-
malaria endemic, industrialized countries with access to the latest technologies and 
sophisticated laboratory equipment (for example, capillary electrophoresis). Should all blood 
samples be sent to reference laboratories in Europe or USA for genotyping analysis? This 
aspect of feasibility in countries where the assessment of antimalarial drug efficacy is 
performed should probably be discussed.  
To our knowledge many laboratories in resource-limited endemic countries (as well as in 
endemic countries with well-developed economies) have the same sophisticated equipment 
as that in Europe/USA, and sometimes more. Second, conducting a PCR-correction is not a 
matter of routine to be performed under remote field conditions. Such drug efficacy studies 
might be conducted in hospitals where lab equipment is not advanced, but the molecular 
analysis of samples collected is rarely done in the same hospital (or health clinic) but is 
always done retrospectively and sent to a research laboratory in the same country, where 
the equipment needed is available. Therefore, we can reassure this reviewer that PCR-
correction assays have been, are, and will be generally conducted in the same endemic 
country as the one where the efficacy study was conducted. 
Page 3: We have added a sentence (at end of paragraph) to clarify that genotyping for PCR-
correction is generally performed within country. 
 
“Many laboratories in endemic countries already have the necessary equipment for 
genotyping so that molecular analyses can be routinely performed within country to 
monitor the effectiveness of their first-line antimalarials.” 
 
Minor comments: 
 
3.2 Page 3, line 7: recrudescence typing and PCR-correction have become 
Corrected 
 
3.3 Page 5, line 10 from the top, LM: Does it stand for light microscopy?  
Yes, corrected.  
 
3.4 Page 5, line 13 from the top, NI: "the more likely NIs are acquired" 
Corrected.  
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3.5 Page 7, line 11 from the top; also line 4 from the bottom, page 8, line 1, "labs": 
laboratories 
All corrected.  
 
3.6 Page 8, line 13: Rwanda 
Corrected. 
 
3.7 Page 8, "pharmacological models can simulate a population of patients in a drug efficacy 
trial…": I am not sure if this statement refers to "Jones et al. in this issue." If not, please 
develop further how pharmacological models can improve analysis of genotyping data.  
We now cite Jaki et al. 2013, which is precursor to this work and describes the basic 
methodology. 
Page 8: This request of Reviewer 3 was addressed as follows: 
 
“Pharmacological models can simulate a population of patients in a drug efficacy 
trial, their therapeutic outcomes, and the genotyping results that would occur at Day 
0 and Day X.16  PCR-corrected failure rates were compared using several molecular 
correction approaches based on simulation models from Jaki and coworkers.16 “ 
 
3.8 Page 9, last paragraph from "The following technical recommendations…": The authors 
present their recommendations here, but their recommendations sound like they are 
mandatory ("should be universally adopted" "mandatory use"). I suggest revising the 
wording of these statements.   
 
Page 10: We have revised the recommendation section as follows:  
“We propose to adopt the following technical procedures: (i) separate PCR reactions 
for each allelic family, rather than multiplex reactions (for msp1 and msp2), which 
improves detection of minority clones; (ii) use of capillary electrophoresis by 
automated sequencer in combination with fluorescently-labelled primers for better 
accuracy of fragment sizing; “ 
Page 10: As already suggested by Reviewer 1, we have added the following paragraph, to 
call for a wider discussion of experts about what should be “universally adopted”.  
“We suggest that improved understanding and technical developments since 
publication of the WHO/MMV consensus protocols (2008) means its 
recommendations should be updated. Another technical meeting should be 
convened, particularly to address the requirements for drug registration trials that 
are more demanding than drug resistance monitoring studies. Regulatory trials 
require precise methodologies and should be implemented as state-of-the-art. The 
present paper could be a basis for the discussion.” 
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3.9 Ref 20 and 32: Please complete the reference volume and/or pages. 
The original citations (numbers of articles in e-Journals) were correct according to PubMed. 
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Summary  
 
Malaria drug trials conducted in endemic areas face a major challenge in their analysis: 
parasitaemia in blood samples collected after treatment may indicate a drug failure or 
originate from a new infection (NI) acquired after treatment. It is therefore vital to reliably 
distinguish drug failures from NI to obtain accurate estimates of drug failure rates. This is 
achieved in Plasmodium falciparum by comparing parasite genotypes obtained at time of 
treatment (the baseline) and on the day of recurring parasitaemia. Such ‘PCR-correction’ is 
required, even for new effective drugs, to obtain accurate failure rates. Despite its routine 
use in surveillance of drug resistance and in clinical drug trials, limitations inherent to the 
molecular genotyping methods have led some commentators to question the validity of 
current PCR-correction strategies. We describe and discuss recent developments in these 
genotyping strategies with particular focus on method validation and limitations.  Our aim is 
to update scientists from public and private bodies working towards the development, 
deployment, and surveillance of new malaria drugs. We aim to promote discussion around 
these issues and argue for the adoption of improved standardized PCR-correction 
methodologies. 
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INTRODUCTION  
Cure rates in clinical trials of antimalarial drugs are based on clinical assessments and 
microscopy conducted during several weeks of post-treatment follow-up. These rates may 
be corrected after genotyping parasites in patient blood samples to distinguish recrudescent 
infections (i.e. those containing parasites that survived drug treatment) from new infections 
(NI) acquired after treatment. In the past years recrudescence typing and PCR-correction 
have become an integral part of malaria drug efficacy trials. The ‘PCR corrected efficacy’ 
excludes all NI from treatment failures and is essential when trials are conducted in high 
transmission areas with frequent NI because, in those areas, even a perfectly efficacious 
drug would have a high apparent failure rate as, without correction, NIs would be mistaken 
for drug failures.  
 
PCR-corrected cure rates and adequate clinical and parasitological response (considered as 
primary endpoints by European Medicines Agency and World Health Organization (WHO) 
are now routinely reported as primary endpoints in regulatory trials of new drugs, yet the 
United States Food and Drug Administration (FDA) requires uncorrected cure rates as 
primary endpoints and FDA’s assessment of PCR-corrected rates is still pending. 
Nonetheless, there is wide consensus that the best available genotyping methodology, 
following a critical and systematic validation, would be highly relevant for regulatory trials of 
antimalarial drugs, because this enables more precise efficacy estimates. 
 
PCR-adjusted outcomes are also accepted as end-points for monitoring drug resistance. 
The WHO widely implements ‘PCR-correction’ in surveillance of drug efficacy in malaria 
endemic areas and recommends changing first-line antimalarial therapy if the PCR-corrected 
failure rate exceeds 10%. Without ‘PCR-correction’ this threshold would be reached in high 
transmission areas even with highly efficient drugs because NIs would be mistaken as drug 
failures. Genotyping is performed on archived blood samples at a later point in time and 
does not inform or influence treatment of recurrent parasitemia. Treatment is always given, 
either per protocol in clinical trials or according to local treatment guidelines in drug efficacy 
monitoring, for all parasitemic episodes. Many laboratories in endemic countries already 
have the necessary equipment for genotyping so that molecular analyses can be routinely 
performed within country to monitor the effectiveness of their first-line antimalarials. 
 
PRINCIPLE OF PCR-CORRECTION  
High frequency of multi-clonal infections is a hallmark of Plasmodium falciparum 
epidemiology, whereby genetically distinct parasite clones persist concurrently and over long 
periods of time.1 The number of concurrent infections in a host (multiplicity of infection) 
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depends on transmission intensity, acquired immunity and other host factors. Patients in 
high-transmission areas harbour a mean of about five parasite clones, and one or two clones 
in regions of intermediate or low transmission.2,3 Highly length-polymorphic P. falciparum 
genes can differentiate these co-infecting clones.  
 
Three molecular markers are routinely genotyped to distinguish NI from recrudescent 
infections in clinical trials of antimalarial drugs, the merozoite surface proteins 1 (msp1) and 
2 (msp2) and glutamate-rich protein (glurp). In 2007 a group of experts, convened by WHO 
and the Medicines for Malaria Venture (MMV), released recommendations for genotyping 
protocols, and a consensus for the analysis of genotyping data and outcome classification 
was presented.4 Any microscopy-positive parasitaemia recurring seven or more days after 
treatment (Day X) is genotyped and compared to the baseline sample (Day 0). 
Recrudescence is defined by a genotype that had already been detected in the blood 
sample taken prior to treatment (i.e. alleles are shared at Day 0 and Day X at all three loci). 
A NI is defined by the absence of a shared allele between Days 0 and X at any of the three 
loci. Molecular correction allows statistical estimation of drug efficacy via survival analysis or 
the WHO ‘per protocol’ method to censor new infections.5 
 
Inherent limitations of currently used genotyping techniques and reluctance of laboratories to 
adopt more precise methods have prompted calls for caution in adopting PCR-correction as 
endpoint.6,7 Two technical problems were singled out as major draw-backs: first, the difficulty 
in detecting all parasite clones present in a blood sample, notably so-called minority clones, 
and second, the limited discriminatory power of gel-electrophoresis to distinguish PCR 
fragments similar in size.6  
 
 
LIMITATIONS INHERENT IN THE CURRENT, WHO/MMV-RECOMMENDED METHOD OF 
PCR-CORRECTION 
In this section, we review limitations of ‘PCR-correction’ and summarize the impact of 
parasite biology on clone detectability. These limitations are often insufficiently 
acknowledged by users and in publications. 
 
A. Biological and epidemiological limitations  
 
Biological constraints resulting in undetected clones 
Parasite clones occasionally remain undetected by PCR despite their presence in the host, 
an observation denoted as ‘imperfect clone detectability’. Imperfect detectability is attributed 
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to sequestration of late P. falciparum stages, a biological characteristic of this species, and 
to naturally acquired immunity leading to fluctuations of parasite densities around the PCR 
detection limit. For example, clone detectability in a host has been estimated at 79% based 
on samples collected 24 hours apart.8 Daily samples of infected children over 14 days 
showed a 48-hour periodicity for some clones.9 Thus, the near-complete sequestration of 
late stages prevents the detection of some clones. One way to improve detectability is by 
taking blood samples on consecutive days. The effect of analyzing consecutive samples 
(Day 0 + Day 1 and Day X + Day X+1) was evaluated10 and shown to significantly increase 
recrudescences. Nevertheless, the WHO/MMV consultation of experts did not recommend 
including extra samples4 as these would be redundant with fast-acting drugs, as most 
patients would be negative by light microscopy on Day 1 and equally at Day X+1 after 
receiving rescue treatment on Day X.  
 
Effects of long follow-up periods and local transmission intensity: the need to 
genotype several markers 
The longer the follow-up period, the more likely NIs are acquired. Thus, PCR-correction 
becomes increasingly important. For drugs with a long half-life, follow-up periods may last for 
63 days. NI accumulating during that period, may contain, purely by chance, an allele 
identical to that present at baseline. This mimics a recrudescence. To counter this effect, 
typing of more markers is crucial.  
 
Even when three markers were analysed, extremes in both low and high transmission cause 
problems for PCR-correction. In intermediate or high malaria transmission areas, a genotype 
can reach 16% allelic frequency,3 whereas in low transmission the parasite population is 
genetically less diverse and the frequency of the most abundant allele may reach 25%. 
Consequently, independent infections can share the same genotype by chance. In the 
context of a drug trial, NIs carrying by chance the same genotype might therefore be 
misclassified as recrudescence leading to overestimation of drug failure.11,12 To prevent this 
error caused by limited genetic diversity in molecular markers, the WHO recommendations 
suggested typing of three markers to confirm a recrudescence.4 In areas of known low 
endemicity or when PCR-corrected failure rates exceed 10%, baseline frequencies should 
be determined from a representative set of admission samples to statistically calculate the 
likelihood of misclassifications. Despite a multi-marker strategy, genotyping methods will 
suffer from lack of discriminatory power in areas with almost clonal parasite population 
structure. In the past, conducting trials under diverse transmission intensity has been 
considered important, but from a genotyping perspective, sites with moderate transmission 
would be ideal.  
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The dangers of low-level genetic signals post-treatment: gametocytes, dying and 
dead asexual parasites 
Early gametocyte stages are susceptible to (some) antimalarials, but only 8-aminoquinolines 
(i.e. primaquine, tafenoquine13) are effective against circulating stage V gametocytes. Most 
current drugs (artemisinin combination therapies; ACTs) are given without 8-aminoquinolines 
(although this may change), so mature gametocytes may persist for few weeks after asexual 
forms have been cleared.14,15 Gametocytes are detectable by PCR and could lead to 
incorrect classification as treatment failures. The WHO/MMV consultation recognised this 
threat and recommended that genotyping should only be performed if asexual parasites had 
been observed by microscopy. The persistence of gametocytes alone was not considered a 
criterion for treatment failure.4 Unpublished results from simulations based on published 
models16 support this recommendation by suggesting that genetic signals from gametocytes 
will have a negligible impact on PCR-correction provided only patients are genotyped that 
are microscopy-positive at Day X. Similarly, ring-specific transcripts were observed until Day 
14 after ACT treatment15, and DNA from parasites persisting at very low levels or, debatably, 
from dead parasites can sometimes be detected by PCR weeks after clearance.17 Like 
gametocytes, these are low-level genetic signals and should be negligible (see below) in 
those patients whose asexual parasitaemia is patent by microscopy. This highlights the 
importance of genotyping only microscopy-positive infections. 
 
 
B. Technical, genotyping limitations  
 
Allelic suppression and detection limit of minority clones 
Systematic investigation of technical limitations has revealed that PCR template competition 
during amplification (allelic suppression) contributes to imperfect detectability of individual 
clones.9,18-21 The detection probability of a genotype depends on its fragment length and the 
ratio of dominant to minority clone, with short fragments more efficiently amplified during 
PCR21. Amplification bias and thus limited detection of minority clones has been observed in 
the past19,22 but their extent and consequences were largely ignored as quantification of such 
effects requires systematic analysis of mixed culture strains. Reciprocal dilution series of two 
precisely quantified strains in increasingly discrepant proportions indicated the following 
results for msp1 and msp2: when a minority clone fragment was longer than the dominant 
clone fragment, it was detectable up to a proportion of 1:5 but not in increasingly discrepant 
ratios. If the minority clone carried a shorter allele (the reciprocal experiment) it was still 
detectable in ratios 1:500 to 1:1’000.21 Importantly, if two genotypes of the same marker 
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belonged to different allelic families and the families were amplified in different reactions, 
then template competition was removed and detection of minority clone was possible to the 
lowest tested ratio of 1:5’000.21 Such excellent sensitivity in detecting minority clones has not 
been reached by methods other than allele-specific PCR.  
 
Sequential genotyping of three markers and questionable suitability of marker glurp 
The sequential typing strategy recommended by WHO/MMV4 has some pitfalls because it 
recommends that no further markers be typed if one marker indicated the presence of a NI 
on Day X. Consequently, if genotyping of the first marker suffered from a technical shortfall 
and erroneously identified a NI, no additional typing result would question that outcome. In 
the past many laboratories have adopted glurp as first marker in sequential typing because 
of its technical simplicity, i.e. only one nPCR was required. However, glurp as first marker 
seems problematic because among all markers glurp suffered from greatest amplification 
bias.21 The large size differences between glurp fragments leads to preferential amplification 
of shorter fragments and loss of larger fragments. A two-fold over-representation of the clone 
with the shortest allele was sufficient to completely suppress detection of three larger 
fragments.21 Loss of genotypes at baseline leads to an overestimation of ‘NI’ and 
consequently results in underestimated treatment failure rates. The usefulness of glurp is 
therefore questionable despite its high polymorphism. However, in trial sites where MOI is 
very low, most infections will be single-clone and clone competition would be largely absent. 
Here glurp, with its large genetic diversity, could be useful as third marker to increase 
discriminative power.  
 
 
HOW CAN WE IMPROVE THE CURRENT WHO/MMV METHOD: CORRECTIVE ACTIONS 
TO MINIMIZE THE IMPACT OF THESE LIMITATIONS 
 
Maximized precision of fragment sizing 
Substantial efforts have been made to overcome the above limitations and improve 
genotyping methodology. One key strategy has been to obtain precise sizing of length-
polymorphic markers by capillary electrophoresis (CE) which has become standard in many 
laboratories.11,23,24 CE is vastly superior to fragment sizing by gel electrophoresis, which had 
a limited resolution to discriminate between similar sized alleles and where unequal loading 
of amounts of PCR products strongly impaired correct sizing. CE has excellent resolution 
and can be considered highly robust if carefully determined cut-offs eliminate stutter peaks. 
Some laboratories still use gels as this is technically simpler and does not require access to 
an automated sequencer.  
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New algorithms for analysis of genotyping data 
Increased appreciation of the technical limitations described above has led to suggestions to 
change the analysis method. One suggested revision (abbreviated as “2/3 approach”) 
demands concordant results from at least two markers to identify a NI or recrudescence. If 
discordant, a third marker, which could be either an established microsatellite marker25-27 or 
glurp, should be genotyped to resolve this sample. Two new approaches to interpret 
genotyping data for PCR-correction were compared to the standard WHO/MMV 
recommendations in a small set of 44 paired samples and revealed substantial differences in 
outcomes.21 A re-analysis of a larger clinical trial conducted in Rwanda by different analysis 
approaches using simulation models16 suggested that these methods differ two-fold in how 
frequently they identify recrudescences (Jones and Hasting, personal communication).  
 
Modelling provides a new approach to validate potential algorithms for interpreting molecular 
data. Pharmacological models can simulate a population of patients in a drug efficacy trial, 
their therapeutic outcomes, and the genotyping results that would occur at Day 0 and Day 
X.16 PCR-corrected failure rates were compared using several molecular correction 
approaches based on simulation models from Jaki and coworkers.16 The “2/3 approach” (i.e. 
using glurp only if msp1 and msp2 results were discordant) provided the best fit with the 
simulated treatment failure rates in a comparison to other molecular correction strategies 
(Figure 1). Adopting the 2/3 approach instead of the current WHO sequential typing method 
led to higher failure rate estimates but these were closer to the theoretical true failure rate. 
  
The current WHO/MMV method and new algorithms currently under investigation (Jones and 
Hastings, personal communication), all seek to define recurrent infections as either NI or 
drug failure. In reality there is often some uncertainty in this decision, and a method 
incorporating this uncertainty could lead to improved efficacy estimates. A Bayesian 
algorithm was developed to adjust drug efficacy for length of microsatellite PCR products 
and population frequency of each genotype detected in paired samples,28 permitting to 
estimate the probability of misclassification and allelic suppression. This highly promising 
new approach incorporates the uncertainty around the classification of NI and 
recrudescence.  
 
 
POSSIBLE USE OF ALTERNATIVE GENOTYPING TECHNIQUES 
This section briefly describes developments with great potential to improve genotyping of P. 
falciparum multiple-clone infections. One suggestion is to identify regions of <500 bp that are 
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rich in single nucleotide polymorphisms (SNP), which can be genotyped by next generation 
sequencing (NGS).29-33 SNP-based typing methods have improved ability to detect minority 
clones: Low-abundant P. falciparum clones can be detected at a ratio of 1:1000 in mixed 
infections.32 In addition, NGS can also quantify the relative abundance of concurrent clones 
in a host.29,31,32 Molecular inversion probes may be useful for highly multiplexed targeted 
sequencing33. NGS-based typing has not yet been validated for molecular correction in 
clinical trials, but its greatly improved sensitivity to detect minor clones suggests an urgent 
need to do so.  
 
Another technique genotypes a large number of SNPs distributed over the entire genome 
(molecular barcode).34 Individual qPCRs using allele-specific probes and high-resolution 
melting curve analysis are performed for all SNPs. Multi-clonal infections will yield mostly 
mixed signals and haplotypes for concurrent clones cannot be established for samples of 
high multiplicity. Barcodes could be suitable for clonal infections in low transmission areas 
but their use in higher transmission areas still needs to be validated.  
 
These methods have the potential to improve detection of minority clones and overcome 
allelic suppression. Thus, these should be validated in clinical trials at high priority. 
Particularly regulatory trials would benefit from state-of-the-art techniques that overcome the 
technical limitations stated above. Yet, biological constraints will remain the same, such as 
sequestration or detection limits for minority clones. For surveillance trials, optimized 
protocols of established typing techniques may be easier implemented than NGS-based 
methods in laboratories in endemic countries.  
 
STEPS FORWARD AND CONCLUSIONS  
The community of technical experts, trial investigators, regulators and policy makers should 
consider rapid adoption of new consensual protocols for genotyping in regulatory malaria 
drug trials, with harmonized laboratory procedures and data analyses. In particular, obtaining 
FDA validation of PCR-correction in drug efficacy trials requires a demonstrably robust 
genotyping strategy generating reproducible results. While the intrinsic biological constraints 
from the parasite’s biology cannot be resolved, all technical issues should be addressed 
jointly by laboratories involved in recrudescence typing. We propose to adopt the following 
technical procedures: (i) separate PCR reactions for each allelic family, rather than multiplex 
reactions (for msp1 and msp2), which improves detection of minority clones; (ii) use of 
capillary electrophoresis by automated sequencer in combination with fluorescently-labelled 
primers for better accuracy of fragment sizing; (iii) markers msp1 and msp2 provide the 
minimal essential data for PCR-correction. If both markers give congruent results (either 
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Recrudescence or NI), no further marker needs be typed; in the case of discrepant results, 
one additional marker should be added (either glurp or new marker); if the “2/3 approach” is 
not possible one should classify the episode as a recrudescence, a stringent interpretation 
that avoids underestimation of treatment failures. During the transition phase both the “2/3” 
and previous WHO/MMV algorithm should be used for backwards compatibility with previous 
studies and to build an evidence base to document the differences between algorithms in 
estimated failure rates; (iv) glurp could still be valuable in low endemicity areas, where it can 
be expected that only one allele is present per sample and no allelic suppression occurs.  
 
PCR-correction is necessary to obtain accurate measures of outcomes in malaria clinical 
trials. The basic methodology, though subject to biological and technical limitations, has 
consistently provided better estimates of drug efficacy in clinical trials than non-PCR-
corrected outcomes. We suggest that improved understanding and technical developments 
since publication of the WHO/MMV consensus protocols (2008) makes it important that its 
recommendations should be updated. Another technical meeting should be convened, 
particularly to address the methodological requirements for drug registration trials that are 
more demanding than drug resistance monitoring studies. Regulatory trials require precise 
methodologies and should be implemented as state-of-the-art. The present paper will serve 
as a basis for discussion towards a revised consensus.  
 
In addition to adopting the “2/3 approach”, Bayesian methodologies should be applied in 
future to incorporate the uncertainty inherent in genotyping. Consensus should be reached 
to implement strictly standardized protocols. PCR-correction should become an acceptable 
and mandatory endpoint in both surveillance and regulatory trials of new drugs. 
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Figure legend 
 
Figure 1: Analysis of simulated trial data for DHA-PPQ with a follow-up period of 42 days. Estimated 
failure rates, calculated using survival analysis, are shown , for no PCR correction  the WHO/MMV 
method of consecutively genotyping the 3 markers msp1, msp2, glurp, and the “2/3 marker” method. 
These estimates were obtained under a range of transmission intensities (the X axis) and can be 
compared to the true failure rate in the simulation i.e. 0.12. The most promising data analysis 
algorithm seemed to be the “2/3 marker” method. Data from Jones and Hastings (personal 
communication) using published simulation models
16
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Summary  
 
Malaria drug trials conducted in endemic areas face a major challenge in their analysis: 
parasitaemia in blood samples collected after treatment may indicate a drug failure or 
originate from a new infection (NI) acquired after treatment. It is therefore vital to reliably 
distinguish drug failures from NI to obtain accurate estimates of drug failure rates. This is 
achieved in Plasmodium falciparum by comparing parasite genotypes obtained at time of 
treatment (the baseline) and on the day of recurring parasitaemia. Such ‘PCR-correction’ is 
required, even for new effective drugs, to obtain accurate failure rates. Despite its routine 
use in surveillance of drug resistance and in clinical drug trials, limitations inherent to the 
molecular genotyping methods have led some commentators to question the validity of 
current PCR-correction strategies. We describe and discuss recent developments in these 
genotyping strategies with particular focus on method validation and limitations.  Our aim is 
to update scientists from public and private bodies working towards the development, 
deployment, and surveillance of new malaria drugs. We aim to promote discussion around 
these issues and argue for the adoption of improved standardized PCR-correction 
methodologies. 
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INTRODUCTION  
Cure rates in clinical trials of antimalarial drugs are based on clinical assessments and 
microscopy conducted during several weeks of post-treatment follow-up. These rates may 
be corrected after genotyping parasites in patient blood samples to distinguish recrudescent 
infections (i.e. those containing parasites that survived drug treatment) from new infections 
(NI) acquired after treatment. In the past years recrudescence typing and PCR-correction 
have become an integral part of malaria drug efficacy trials. The ‘PCR corrected efficacy’ 
excludes all NI from treatment failures and is essential when trials are conducted in high 
transmission areas with frequent NI because, in those areas, even a perfectly efficacious 
drug would have a high apparent failure rate as, without correction, NIs would be mistaken 
for drug failures.  
 
PCR-corrected cure rates and adequate clinical and parasitological response (considered as 
primary endpoints by European Medicines Agency and World Health Organization (WHO) 
are now routinely reported as primary endpoints in regulatory trials of new drugs, yet the 
United States Food and Drug Administration (FDA) requires uncorrected cure rates as 
primary endpoints and FDA’s assessment of PCR-corrected rates is still pending. 
Nonetheless, there is wide consensus that the best available genotyping methodology, 
following a critical and systematic validation, would be highly relevant for regulatory trials of 
antimalarial drugs, because this enables more precise efficacy estimates. 
 
PCR-adjusted outcomes are also accepted as end-points for monitoring drug resistance. 
The WHO widely implements ‘PCR-correction’ in surveillance of drug efficacy in malaria 
endemic areas and recommends changing first-line antimalarial therapy if the PCR-corrected 
failure rate exceeds 10%. Without ‘PCR-correction’ this threshold would be reached in high 
transmission areas even with highly efficient drugs because NIs would be mistaken as drug 
failures. Genotyping is performed on archived blood samples at a later point in time and 
does not inform or influence treatment of recurrent parasitemia. Treatment is always given, 
either per protocol in clinical trials or according to local treatment guidelines in drug efficacy 
monitoring, for all parasitemic episodes. Many laboratories in endemic countries already 
have the necessary equipment for genotyping so that molecular analyses can be routinely 
performed within country to monitor the effectiveness of their first-line antimalarials. 
 
PRINCIPLE OF PCR-CORRECTION  
High frequency of multi-clonal infections is a hallmark of Plasmodium falciparum 
epidemiology, whereby genetically distinct parasite clones persist concurrently and over long 
periods of time.1 The number of concurrent infections in a host (multiplicity of infection) 
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depends on transmission intensity, acquired immunity and other host factors. Patients in 
high-transmission areas harbour a mean of about five parasite clones, and one or two clones 
in regions of intermediate or low transmission.2,3 Highly length-polymorphic P. falciparum 
genes can differentiate these co-infecting clones.  
 
Three molecular markers are routinely genotyped to distinguish NI from recrudescent 
infections in clinical trials of antimalarial drugs, the merozoite surface proteins 1 (msp1) and 
2 (msp2) and glutamate-rich protein (glurp). In 2007 a group of experts, convened by WHO 
and the Medicines for Malaria Venture (MMV), released recommendations for genotyping 
protocols, and a consensus for the analysis of genotyping data and outcome classification 
was presented.4 Any microscopy-positive parasitaemia recurring seven or more days after 
treatment (Day X) is genotyped and compared to the baseline sample (Day 0). 
Recrudescence is defined by a genotype that had already been detected in the blood 
sample taken prior to treatment (i.e. alleles are shared at Day 0 and Day X at all three loci). 
A NI is defined by the absence of a shared allele between Days 0 and X at any of the three 
loci. Molecular correction allows statistical estimation of drug efficacy via survival analysis or 
the WHO ‘per protocol’ method to censor new infections.5 
 
Inherent limitations of currently used genotyping techniques and reluctance of laboratories to 
adopt more precise methods have prompted calls for caution in adopting PCR-correction as 
endpoint.6,7 Two technical problems were singled out as major draw-backs: first, the difficulty 
in detecting all parasite clones present in a blood sample, notably so-called minority clones, 
and second, the limited discriminatory power of gel-electrophoresis to distinguish PCR 
fragments similar in size.6  
 
 
LIMITATIONS INHERENT IN THE CURRENT, WHO/MMV-RECOMMENDED METHOD OF 
PCR-CORRECTION 
In this section, we review limitations of ‘PCR-correction’ and summarize the impact of 
parasite biology on clone detectability. These limitations are often insufficiently 
acknowledged by users and in publications. 
 
A. Biological and epidemiological limitations  
 
Biological constraints resulting in undetected clones 
Parasite clones occasionally remain undetected by PCR despite their presence in the host, 
an observation denoted as ‘imperfect clone detectability’. Imperfect detectability is attributed 
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to sequestration of late P. falciparum stages, a biological characteristic of this species, and 
to naturally acquired immunity leading to fluctuations of parasite densities around the PCR 
detection limit. For example, clone detectability in a host has been estimated at 79% based 
on samples collected 24 hours apart.8 Daily samples of infected children over 14 days 
showed a 48-hour periodicity for some clones.9 Thus, the near-complete sequestration of 
late stages prevents the detection of some clones. One way to improve detectability is by 
taking blood samples on consecutive days. The effect of analyzing consecutive samples 
(Day 0 + Day 1 and Day X + Day X+1) was evaluated10 and shown to significantly increase 
recrudescences. Nevertheless, the WHO/MMV consultation of experts did not recommend 
including extra samples4 as these would be redundant with fast-acting drugs, as most 
patients would be negative by light microscopy on Day 1 and equally at Day X+1 after 
receiving rescue treatment on Day X.  
 
Effects of long follow-up periods and local transmission intensity: the need to 
genotype several markers 
The longer the follow-up period, the more likely NIs are acquired. Thus, PCR-correction 
becomes increasingly important. For drugs with a long half-life, follow-up periods may last for 
63 days. NI accumulating during that period, may contain, purely by chance, an allele 
identical to that present at baseline. This mimics a recrudescence. To counter this effect, 
typing of more markers is crucial.  
 
Even when three markers were analysed, extremes in both low and high transmission cause 
problems for PCR-correction. In intermediate or high malaria transmission areas, a genotype 
can reach 16% allelic frequency,3 whereas in low transmission the parasite population is 
genetically less diverse and the frequency of the most abundant allele may reach 25%. 
Consequently, independent infections can share the same genotype by chance. In the 
context of a drug trial, NIs carrying by chance the same genotype might therefore be 
misclassified as recrudescence leading to overestimation of drug failure.11,12 To prevent this 
error caused by limited genetic diversity in molecular markers, the WHO recommendations 
suggested typing of three markers to confirm a recrudescence.4 In areas of known low 
endemicity or when PCR-corrected failure rates exceed 10%, baseline frequencies should 
be determined from a representative set of admission samples to statistically calculate the 
likelihood of misclassifications. Despite a multi-marker strategy, genotyping methods will 
suffer from lack of discriminatory power in areas with almost clonal parasite population 
structure. In the past, conducting trials under diverse transmission intensity has been 
considered important, but from a genotyping perspective, sites with moderate transmission 
would be ideal.  
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The dangers of low-level genetic signals post-treatment: gametocytes, dying and 
dead asexual parasites 
Early gametocyte stages are susceptible to (some) antimalarials, but only 8-aminoquinolines 
(i.e. primaquine, tafenoquine13) are effective against circulating stage V gametocytes. Most 
current drugs (artemisinin combination therapies; ACTs) are given without 8-aminoquinolines 
(although this may change), so mature gametocytes may persist for few weeks after asexual 
forms have been cleared.14,15 Gametocytes are detectable by PCR and could lead to 
incorrect classification as treatment failures. The WHO/MMV consultation recognised this 
threat and recommended that genotyping should only be performed if asexual parasites had 
been observed by microscopy. The persistence of gametocytes alone was not considered a 
criterion for treatment failure.4 Unpublished results from simulations based on published 
models16 support this recommendation by suggesting that genetic signals from gametocytes 
will have a negligible impact on PCR-correction provided only patients are genotyped that 
are microscopy-positive at Day X. Similarly, ring-specific transcripts were observed until Day 
14 after ACT treatment15, and DNA from parasites persisting at very low levels or, debatably, 
from dead parasites can sometimes be detected by PCR weeks after clearance.17 Like 
gametocytes, these are low-level genetic signals and should be negligible (see below) in 
those patients whose asexual parasitaemia is patent by microscopy. This highlights the 
importance of genotyping only microscopy-positive infections. 
 
 
B. Technical, genotyping limitations  
 
Allelic suppression and detection limit of minority clones 
Systematic investigation of technical limitations has revealed that PCR template competition 
during amplification (allelic suppression) contributes to imperfect detectability of individual 
clones.9,18-21 The detection probability of a genotype depends on its fragment length and the 
ratio of dominant to minority clone, with short fragments more efficiently amplified during 
PCR21. Amplification bias and thus limited detection of minority clones has been observed in 
the past19,22 but their extent and consequences were largely ignored as quantification of such 
effects requires systematic analysis of mixed culture strains. Reciprocal dilution series of two 
precisely quantified strains in increasingly discrepant proportions indicated the following 
results for msp1 and msp2: when a minority clone fragment was longer than the dominant 
clone fragment, it was detectable up to a proportion of 1:5 but not in increasingly discrepant 
ratios. If the minority clone carried a shorter allele (the reciprocal experiment) it was still 
detectable in ratios 1:500 to 1:1’000.21 Importantly, if two genotypes of the same marker 
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belonged to different allelic families and the families were amplified in different reactions, 
then template competition was removed and detection of minority clone was possible to the 
lowest tested ratio of 1:5’000.21 Such excellent sensitivity in detecting minority clones has not 
been reached by methods other than allele-specific PCR.  
 
Sequential genotyping of three markers and questionable suitability of marker glurp 
The sequential typing strategy recommended by WHO/MMV4 has some pitfalls because it 
recommends that no further markers be typed if one marker indicated the presence of a NI 
on Day X. Consequently, if genotyping of the first marker suffered from a technical shortfall 
and erroneously identified a NI, no additional typing result would question that outcome. In 
the past many laboratories have adopted glurp as first marker in sequential typing because 
of its technical simplicity, i.e. only one nPCR was required. However, glurp as first marker 
seems problematic because among all markers glurp suffered from greatest amplification 
bias.21 The large size differences between glurp fragments leads to preferential amplification 
of shorter fragments and loss of larger fragments. A two-fold over-representation of the clone 
with the shortest allele was sufficient to completely suppress detection of three larger 
fragments.21 Loss of genotypes at baseline leads to an overestimation of ‘NI’ and 
consequently results in underestimated treatment failure rates. The usefulness of glurp is 
therefore questionable despite its high polymorphism. However, in trial sites where MOI is 
very low, most infections will be single-clone and clone competition would be largely absent. 
Here glurp, with its large genetic diversity, could be useful as third marker to increase 
discriminative power.  
 
 
HOW CAN WE IMPROVE THE CURRENT WHO/MMV METHOD: CORRECTIVE ACTIONS 
TO MINIMIZE THE IMPACT OF THESE LIMITATIONS 
 
Maximized precision of fragment sizing 
Substantial efforts have been made to overcome the above limitations and improve 
genotyping methodology. One key strategy has been to obtain precise sizing of length-
polymorphic markers by capillary electrophoresis (CE) which has become standard in many 
laboratories.11,23,24 CE is vastly superior to fragment sizing by gel electrophoresis, which had 
a limited resolution to discriminate between similar sized alleles and where unequal loading 
of amounts of PCR products strongly impaired correct sizing. CE has excellent resolution 
and can be considered highly robust if carefully determined cut-offs eliminate stutter peaks. 
Some laboratories still use gels as this is technically simpler and does not require access to 
an automated sequencer.  
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New algorithms for analysis of genotyping data 
Increased appreciation of the technical limitations described above has led to suggestions to 
change the analysis method. One suggested revision (abbreviated as “2/3 approach”) 
demands concordant results from at least two markers to identify a NI or recrudescence. If 
discordant, a third marker, which could be either an established microsatellite marker25-27 or 
glurp, should be genotyped to resolve this sample. Two new approaches to interpret 
genotyping data for PCR-correction were compared to the standard WHO/MMV 
recommendations in a small set of 44 paired samples and revealed substantial differences in 
outcomes.21 A re-analysis of a larger clinical trial conducted in Rwanda by different analysis 
approaches using simulation models16 suggested that these methods differ two-fold in how 
frequently they identify recrudescences (Jones and Hasting, personal communication).  
 
Modelling provides a new approach to validate potential algorithms for interpreting molecular 
data. Pharmacological models can simulate a population of patients in a drug efficacy trial, 
their therapeutic outcomes, and the genotyping results that would occur at Day 0 and Day 
X.16 PCR-corrected failure rates were compared using several molecular correction 
approaches based on simulation models from Jaki and coworkers.16 The “2/3 approach” (i.e. 
using glurp only if msp1 and msp2 results were discordant) provided the best fit with the 
simulated treatment failure rates in a comparison to other molecular correction strategies 
(Figure 1). Adopting the 2/3 approach instead of the current WHO sequential typing method 
led to higher failure rate estimates but these were closer to the theoretical true failure rate. 
  
The current WHO/MMV method and new algorithms currently under investigation (Jones and 
Hastings, personal communication), all seek to define recurrent infections as either NI or 
drug failure. In reality there is often some uncertainty in this decision, and a method 
incorporating this uncertainty could lead to improved efficacy estimates. A Bayesian 
algorithm was developed to adjust drug efficacy for length of microsatellite PCR products 
and population frequency of each genotype detected in paired samples,28 permitting to 
estimate the probability of misclassification and allelic suppression. This highly promising 
new approach incorporates the uncertainty around the classification of NI and 
recrudescence.  
 
 
POSSIBLE USE OF ALTERNATIVE GENOTYPING TECHNIQUES 
This section briefly describes developments with great potential to improve genotyping of P. 
falciparum multiple-clone infections. One suggestion is to identify regions of <500 bp that are 
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rich in single nucleotide polymorphisms (SNP), which can be genotyped by next generation 
sequencing (NGS).29-33 SNP-based typing methods have improved ability to detect minority 
clones: Low-abundant P. falciparum clones can be detected at a ratio of 1:1000 in mixed 
infections.32 In addition, NGS can also quantify the relative abundance of concurrent clones 
in a host.29,31,32 Molecular inversion probes may be useful for highly multiplexed targeted 
sequencing33. NGS-based typing has not yet been validated for molecular correction in 
clinical trials, but its greatly improved sensitivity to detect minor clones suggests an urgent 
need to do so.  
 
Another technique genotypes a large number of SNPs distributed over the entire genome 
(molecular barcode).34 Individual qPCRs using allele-specific probes and high-resolution 
melting curve analysis are performed for all SNPs. Multi-clonal infections will yield mostly 
mixed signals and haplotypes for concurrent clones cannot be established for samples of 
high multiplicity. Barcodes could be suitable for clonal infections in low transmission areas 
but their use in higher transmission areas still needs to be validated.  
 
These methods have the potential to improve detection of minority clones and overcome 
allelic suppression. Thus, these should be validated in clinical trials at high priority. 
Particularly regulatory trials would benefit from state-of-the-art techniques that overcome the 
technical limitations stated above. Yet, biological constraints will remain the same, such as 
sequestration or detection limits for minority clones. For surveillance trials, optimized 
protocols of established typing techniques may be easier implemented than NGS-based 
methods in laboratories in endemic countries.  
 
STEPS FORWARD AND CONCLUSIONS  
The community of technical experts, trial investigators, regulators and policy makers should 
consider rapid adoption of new consensual protocols for genotyping in regulatory malaria 
drug trials, with harmonized laboratory procedures and data analyses. In particular, obtaining 
FDA validation of PCR-correction in drug efficacy trials requires a demonstrably robust 
genotyping strategy generating reproducible results. While the intrinsic biological constraints 
from the parasite’s biology cannot be resolved, all technical issues should be addressed 
jointly by laboratories involved in recrudescence typing. We propose to adopt the following 
technical procedures: (i) separate PCR reactions for each allelic family, rather than multiplex 
reactions (for msp1 and msp2), which improves detection of minority clones; (ii) use of 
capillary electrophoresis by automated sequencer in combination with fluorescently-labelled 
primers for better accuracy of fragment sizing; (iii) markers msp1 and msp2 provide the 
minimal essential data for PCR-correction. If both markers give congruent results (either 
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Recrudescence or NI), no further marker needs be typed; in the case of discrepant results, 
one additional marker should be added (either glurp or new marker); if the “2/3 approach” is 
not possible one should classify the episode as a recrudescence, a stringent interpretation 
that avoids underestimation of treatment failures. During the transition phase both the “2/3” 
and previous WHO/MMV algorithm should be used for backwards compatibility with previous 
studies and to build an evidence base to document the differences between algorithms in 
estimated failure rates; (iv) glurp could still be valuable in low endemicity areas, where it can 
be expected that only one allele is present per sample and no allelic suppression occurs.  
 
PCR-correction is necessary to obtain accurate measures of outcomes in malaria clinical 
trials. The basic methodology, though subject to biological and technical limitations, has 
consistently provided better estimates of drug efficacy in clinical trials than non-PCR-
corrected outcomes. We suggest that improved understanding and technical developments 
since publication of the WHO/MMV consensus protocols (2008) makes it important that its 
recommendations should be updated. Another technical meeting should be convened, 
particularly to address the methodological requirements for drug registration trials that are 
more demanding than drug resistance monitoring studies. Regulatory trials require precise 
methodologies and should be implemented as state-of-the-art. The present paper will serve 
as a basis for discussion towards a revised consensus.  
 
In addition to adopting the “2/3 approach”, Bayesian methodologies should be applied in 
future to incorporate the uncertainty inherent in genotyping. Consensus should be reached 
to implement strictly standardized protocols. PCR-correction should become an acceptable 
and mandatory endpoint in both surveillance and regulatory trials of new drugs. 
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Figure legend 
 
Figure 1: Analysis of simulated trial data for DHA-PPQ with a follow-up period of 42 days. Estimated 
failure rates, calculated using survival analysis, are shown , for no PCR correction  the WHO/MMV 
method of consecutively genotyping the 3 markers msp1, msp2, glurp, and the “2/3 marker” method. 
These estimates were obtained under a range of transmission intensities (the X axis) and can be 
compared to the true failure rate in the simulation i.e. 0.12. The most promising data analysis 
algorithm seemed to be the “2/3 marker” method. Data from Jones and Hastings (personal 
communication) using published simulation models
16
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